SOURCE: diaDexus, Inc.

Diadexus, Inc.

October 13, 2015 09:15 ET

Diadexus, Inc. Names Jonathan Ruais as Vice President of Marketing

SOUTH SAN FRANCISCO, CA--(Marketwired - Oct 13, 2015) - Diadexus, Inc. (OTCQB: DDXS), a diagnostics company developing and commercializing products that aid in the prediction of cardiac disease risk, today announced that Jonathan Ruais has joined the Company as Vice President of Marketing. Mr. Ruais brings over 15 years of leadership experience to Diadexus, including nearly 10 years as a highly accomplished marketing executive in the medical industry. In his new role at Diadexus, Mr. Ruais will be responsible for developing and executing the Company's marketing programs, including helping drive awareness and adoption of PLAC® Activity within the hospital and lab channels and supporting the launch of proADM for acute episodes of heart failure.

"Jon brings a deep understanding of the heart failure market along with extensive experience in the marketing of novel cardiovascular brands, as well as life cycle management of established products," said Lori Rafield, Ph.D., chairman and chief executive officer of Diadexus. "His expertise will be invaluable as we execute our commercial strategy for PLAC® Activity and advance development of ProADM, our heart failure diagnostic biomarker for which we expect to file a regulatory submission in early 2016. Our continued ability to attract highly experienced management to the Diadexus team reflects the strong commercial potential of our product portfolio."

"There is a significant need in the marketplace for actionable information to predict and reduce cardiovascular events in patients at risk," said Mr. Ruais. "I look forward to leading the Diadexus marketing team to ensure the successful commercialization of this unique cardiovascular product portfolio."

Mr. Ruais joins Diadexus from Thoratec Corporation where he first served as Senior Global Business Unit Director, Commercial Operations, where he managed the commercial operations for HeartMate II® and HeartMate 3™, Thoratec's lead therapies addressing advanced-stage heart failure. His time at Thoratec culminated in his appointment as Senior Director, Global Strategic Marketing, where he led the company's strategic marketing organization, long term strategy development and new product launches. Prior to joining Thoratec in 2011, Mr. Ruais held several product management and marketing positions in the Neuromodulation Division at St. Jude Medical, most recently as Director of Chronic Pain Therapy Management. From 2000 to 2006, Mr. Ruais served as a lieutenant and nuclear submarine power engineer in the United States Navy. Mr. Ruais holds a B.A. in Political Science from George Washington University and an M.B.A. from the University of Western Florida.

About Diadexus, Inc.
Diadexus, based in South San Francisco, California, is a diagnostics company developing and commercializing products that aid in the prediction of cardiac disease risk, providing healthcare providers with actionable information for managing patients. The Company pioneered the testing of Lp-PLA2, a marker of vascular-specific inflammation that provides new information, over and above traditional risk factors measured in a lipid panel, and has over a decade of peer-reviewed literature validating its utility. Diadexus' products, The PLAC® Test ELISA Kit, first cleared by the FDA in 2003, and The PLAC® Test for Lp-PLA2 Activity, cleared in December 2014, are the only two FDA-cleared tests to measure Lp-PLA2.

The Company also has a pipeline of biomarkers for heart failure, proADM, proET-1 and proANP, with each providing distinct, additive information for healthcare providers over currently available markers. Diadexus also provides services to pharmaceutical partners to address the need to incorporate biomarkers in clinical development. To learn more about the PLAC® tests, please visit www.plactest.com, or visit the Company's website at www.diadexus.com.

Forward-Looking Statements
This release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements related to the therapeutic and commercial potential of our product portfolio, development and expected timing of the regulatory submission for ProADM. Forward-looking statements are based on current expectations and assumptions and entail various risks and uncertainties that could cause actual results to differ materially from those expressed in such forward-looking statements. Important factors known to us that could cause actual results to differ materially from those expressed in such forward-looking statements include the potential for success of and timing of when our development efforts may be completed; our ability to develop proADM for regulatory submission; our ability to successfully integrate our new management leadership; our ability to continue to build our heart failure franchise; our ability to identify and build products with additional biomarkers; sales of our PLAC® Test products in the marketplace; our ability to grow revenues from existing and new customers; product pricing and demand with a concentrated customer base; the continued focus of regulatory agencies and payors on costs and our laboratory customer practices; relationships with key customers; third party payors' acceptance of and reimbursement for the PLAC® Tests; our ability to continue to manufacture the PLAC® Tests to meet customer demand; the adequacy of our intellectual property rights and our ability to maintain a proprietary position for our lead product; our limited revenue and cash resources. Additional factors that could cause our results to differ materially from those described in the forward-looking statements can be found in our most recent quarterly report on Form 10-Q, and other reports filed with the Securities and Exchange Commission, and available at the SEC's web site at www.sec.gov. The information set forth herein speaks only as of the date hereof, and except as required by law, we disclaim any intention and does not assume any obligation to update or revise any forward looking statement, whether as a result of new information, future events or otherwise.

Contact Information

  • CONTACTS:

    Company Contact:
    Leone Patterson
    Chief Financial Officer
    (650) 246-6400
    Email Contact